The first licensed dengue vaccine: can it be used in travelers?
Purpose of review: The first dengue vaccine (Dengvaxia) was endorsed by the European Medicine Agency and the US Food and Drug Administration. Given the excess risk of severe dengue in seronegative vaccinees, use is restricted to seropositive individuals. Dengvaxia confers high protection against sev...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 1, 2019
|
| In: |
Current opinion in infectious diseases
Year: 2019, Jahrgang: 32, Heft: 5, Pages: 394-400 |
| ISSN: | 1473-6527 |
| DOI: | 10.1097/QCO.0000000000000573 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1097/QCO.0000000000000573 Verlag: https://journals.lww.com/co-infectiousdiseases/Abstract/2019/10000/The_first_licensed_dengue_vaccine__can_it_be_used.4.aspx 
|
| Verfasserangaben: | Annelies Wilder-Smith |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1690125950 | ||
| 003 | DE-627 | ||
| 005 | 20240404193233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200217s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QCO.0000000000000573 |2 doi | |
| 035 | |a (DE-627)1690125950 | ||
| 035 | |a (DE-599)KXP1690125950 | ||
| 035 | |a (OCoLC)1341305486 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wilder-Smith, Annelies |e VerfasserIn |0 (DE-588)1064971458 |0 (DE-627)815377339 |0 (DE-576)186940998 |4 aut | |
| 245 | 1 | 4 | |a The first licensed dengue vaccine |b can it be used in travelers? |c Annelies Wilder-Smith |
| 264 | 1 | |c October 1, 2019 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.02.2020 | ||
| 520 | |a Purpose of review: The first dengue vaccine (Dengvaxia) was endorsed by the European Medicine Agency and the US Food and Drug Administration. Given the excess risk of severe dengue in seronegative vaccinees, use is restricted to seropositive individuals. Dengvaxia confers high protection against severe dengue in seropositive vaccinees. - Recent findings: With increasing global travel, the probability of travelers being seropositive increases. Such seropositive travelers may be at increased risk of severe dengue as a result of a second dengue infection during repeat travel. Nevertheless, the use of Dengvaxia in travelers requires a careful analysis of all the factors. Seropositive travelers only present a minority of all travelers. A validated rapid diagnostic test to screen for dengue serostatus is not yet available. Such a test should be highly specific to avoid inadvertent vaccination of seronegative individuals. The three-dose regimen precludes the use in most travelers who tend to present at travel clinics less than 6 weeks prior to departure. Furthermore, questions about potential sub-optimal immunogenicity in seropositives in nonendemic settings, and the need and timing of boosters remain unanswered. - Summary: Although there could potentially be substantial protection against severe dengue in seropositive travelers, Dengvaxia is far from an ideal travel vaccine. | ||
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in infectious diseases |d London : Lippincott Williams & Wilkins, 1988 |g 32(2019), 5, Seite 394-400 |h Online-Ressource |w (DE-627)32445595X |w (DE-600)2026993-6 |w (DE-576)093981171 |x 1473-6527 |7 nnas |a The first licensed dengue vaccine can it be used in travelers? |
| 773 | 1 | 8 | |g volume:32 |g year:2019 |g number:5 |g pages:394-400 |g extent:7 |a The first licensed dengue vaccine can it be used in travelers? |
| 856 | 4 | 0 | |u https://doi.org/10.1097/QCO.0000000000000573 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/co-infectiousdiseases/Abstract/2019/10000/The_first_licensed_dengue_vaccine__can_it_be_used.4.aspx |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200217 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1064971458 |a Wilder-Smith, Annelies |m 1064971458:Wilder-Smith, Annelies |d 910000 |d 912800 |d 50000 |e 910000PW1064971458 |e 912800PW1064971458 |e 50000PW1064971458 |k 0/910000/ |k 1/910000/912800/ |k 0/50000/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1690125950 |e 3595955056 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Annelies","family":"Wilder-Smith","role":"aut","roleDisplay":"VerfasserIn","display":"Wilder-Smith, Annelies"}],"title":[{"subtitle":"can it be used in travelers?","title":"The first licensed dengue vaccine","title_sort":"first licensed dengue vaccine"}],"language":["eng"],"recId":"1690125950","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 17.02.2020"],"name":{"displayForm":["Annelies Wilder-Smith"]},"id":{"eki":["1690125950"],"doi":["10.1097/QCO.0000000000000573"]},"origin":[{"dateIssuedDisp":"October 1, 2019","dateIssuedKey":"2019"}],"relHost":[{"title":[{"title":"Current opinion in infectious diseases","title_sort":"Current opinion in infectious diseases"}],"part":{"year":"2019","pages":"394-400","issue":"5","volume":"32","text":"32(2019), 5, Seite 394-400","extent":"7"},"pubHistory":["1.1988 -"],"recId":"32445595X","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"The first licensed dengue vaccine can it be used in travelers?Current opinion in infectious diseases","note":["Gesehen am 29.01.03"],"id":{"eki":["32445595X"],"zdb":["2026993-6"],"issn":["1473-6527","1535-3877"]},"origin":[{"publisherPlace":"London ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1988","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedDisp":"1988-"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"7 S."}]} | ||
| SRT | |a WILDERSMITFIRSTLICEN1201 | ||